



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: January 21, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Unaudited financial results for the third quarter and nine months ended on December 31, 2021 (Revised)

This has reference to our letter dated January 21, 2022 regarding submission of Unaudited Financial Results for the Quarter and nine months ended December 31, 2021 pursuant to regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

In this connection, we would like to inform that the aforesaid unaudited results submitted to stock exchanges contain clerical error caused inadvertently.

Since only the Sr. No. VII & XV contains error, we affirm that there are no other changes in the Statement of Unaudited Financial Results for the for the Quarter and nine months ended December 31, 2021.

We sincerely regret the inconvenience caused in this regard.

Kindly take revised Unaudited Financial Statement on your records.

Thanking you,

Yours faithfully,
For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063. Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011

CIN: U51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.- Khed, Dist.- Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

SUPRIYA LIFESCIENCE LIMITED
 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: U51900MH2008PLC180452
 Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com
UNAUDITED FINANCIAL RESULTS
 FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2021

Rs. in Millions, except per share data


Part I -Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months Ended 31st December ,2021

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine Months	Nine Months Ended	Year ended
		31-12-2021	30-09-2021	31-12-2020	Ended	31-12-2020	31-03-2021
		Unaudited*	Unaudited*	Unaudited*	31-12-2021	Unaudited*	Audited*
					Unaudited*		
	Income						
I	Revenue from Operations	1,170.00	1,480.06	806.91	3,418.00	2,557.17	3,853.66
II	Other Income	54.42	31.73	43.29	107.02	106.01	108.56
III	Total Income	1,224.41	1,511.80	850.20	3,525.02	2,663.18	3,962.21
2	Expenses						
	a) Cost of Materials Consumed	722.27	464.36	421.98	1,605.88	990.75	1,405.71
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	-304.35	-28.22	-94.43	-356.15	-6.67	-124.45
	d. Employee benefit expenses	184.29	94.04	107.64	362.09	234.72	327.61
	e. Finance Cost	11.49	10.58	8.14	31.81	65.44	40.80
	f. Depreciation & amortisation expense	25.99	24.63	47.91	75.39	49.77	67.61
	g. Other expenditure	184.03	168.87	113.43	488.36	312.49	571.83
IV	Total Expenses	823.72	734.26	604.67	2,207.37	1,646.51	2,289.11
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	400.70	777.54	245.53	1,317.65	1,016.67	1,673.10
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	400.00	777.54	245.53	1,317.65	1,016.67	1,673.10
VIII	Tax Expense						
	a) Current Tax	124.16	197.23	85.12	337.44	255.37	430.22
	b) Deferred Tax	-119.86	-1.90	3.48	-75.79	10.44	6.94
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-5.27	-0.56	-0.75	-5.77	-2.25	-1.66
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.33	0.14	0.19	1.45	0.57	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	392.46	581.78	156.37	1,051.67	749.18	1,234.69
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89



1. The above Unaudited Standalone Financial Results of the company were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 21st of January 2022.
2. The above financial results have been prepared in accordance with the Companies (Indian accounting Standards) Rules, 2015 (Ind AS as amended), prescribed u/s 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
3. The company has taken into account the possible impacts of COVID-19 in preparation of the above standalone financial results, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenue and on cost budgets in respect of fixed price contracts, impact on leases and impact on effectiveness of its hedging relationships. The Company has considered internal and certain external sources of information including reliable credit reports, economic forecasts and industry reports up to the date of approval of above standalone financial results and expects to recover the carrying amount of its assets. The impact of COVID-19 on the standalone financial results may differ from that estimated as at the date of approval of the standalone financial results.
4. Figures for previous periods have been regrouped / reclassified wherever considered necessary.

For Supriya Lifescience Limited



Satish Wagh
Chairman & Managing Director



Date: January 21, 2022

Place: Mumbai